MX2022000904A - Inhibidores de arginasa y métodos de uso de estos. - Google Patents

Inhibidores de arginasa y métodos de uso de estos.

Info

Publication number
MX2022000904A
MX2022000904A MX2022000904A MX2022000904A MX2022000904A MX 2022000904 A MX2022000904 A MX 2022000904A MX 2022000904 A MX2022000904 A MX 2022000904A MX 2022000904 A MX2022000904 A MX 2022000904A MX 2022000904 A MX2022000904 A MX 2022000904A
Authority
MX
Mexico
Prior art keywords
sub
sup
hydrogen
methods
alkyl
Prior art date
Application number
MX2022000904A
Other languages
English (en)
Inventor
Iain Simpson
Sameer Kawatkar
Qing Ye
Xiaolan Zheng
Scott Nathan Mlynarski
Jason Shields
Haixia Wang
Ray Finlay
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2022000904A publication Critical patent/MX2022000904A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se divulgan compuestos de fórmula (I), o sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que los comprenden y métodos para tratar el cáncer o una enfermedad inflamatoria respiratoria utilizándolos: (VER FORMULA) donde R1 se selecciona entre hidrógeno, -CH3 y -(C=O)CH(R1a)NH2; R1a es alquilo C1-C4; Y es -(CH2)n- o -(C=O)-; n es un número entero seleccionado entre 1 y 2; R2 se selecciona entre hidrógeno, -CH3 y -(C=X)R4 y R3 es hidrógeno o -CH3; o R2 y R3 , junto con el nitrógeno al que están unidos, se conectan para formar un anillo heterocíclico de 6 miembros; X es NH u O; R4 es -CH3 o -[CH(R4a)]mNH2; m es un número entero seleccionado entre 0 o 1; y R4a es hidrógeno o alquilo C1-C6.
MX2022000904A 2019-07-23 2020-07-22 Inhibidores de arginasa y métodos de uso de estos. MX2022000904A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877407P 2019-07-23 2019-07-23
PCT/IB2020/056899 WO2021014380A1 (en) 2019-07-23 2020-07-22 Arginase inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022000904A true MX2022000904A (es) 2022-05-02

Family

ID=71842723

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000904A MX2022000904A (es) 2019-07-23 2020-07-22 Inhibidores de arginasa y métodos de uso de estos.

Country Status (9)

Country Link
US (1) US20220267356A1 (es)
EP (1) EP4004004A1 (es)
JP (1) JP2022541592A (es)
KR (1) KR20220038105A (es)
CN (1) CN114127081A (es)
AU (1) AU2020319132B2 (es)
CA (1) CA3147226A1 (es)
MX (1) MX2022000904A (es)
WO (1) WO2021014380A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729936T3 (es) * 2010-04-22 2019-11-07 Mars Inc Inhibidores de arginasa y sus aplicaciones terapéuticas
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) * 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity

Also Published As

Publication number Publication date
AU2020319132A1 (en) 2022-03-10
KR20220038105A (ko) 2022-03-25
WO2021014380A1 (en) 2021-01-28
AU2020319132B2 (en) 2023-09-07
CA3147226A1 (en) 2021-01-28
EP4004004A1 (en) 2022-06-01
CN114127081A (zh) 2022-03-01
JP2022541592A (ja) 2022-09-26
US20220267356A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
PH12021550310A1 (en) Novel sulfonamideurea compounds
MX2022014312A (es) Inhibidores de sarcomero cardiaco.
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
MX9804457A (es) Inhibidores de las metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y metodos y compuestos intermedios utiles para su preparacion.
RU2003122190A (ru) Производные тетрагидропиридина, их получение и применение в качестве ингибиторов клеточной пролиферации
DE69501947T2 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
JP2013531029A5 (es)
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
HUP9902459A2 (hu) Szubsztituált indazolszármazékok és felhasználásuk IV-típusú foszfodiészteráz (PDE) aktivitásának, és a tumornekrózis-faktor (TNF) keletkezésének gátlására
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
EA200701780A1 (ru) Противоопухолевое средство
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
RU2010101611A (ru) Полициклические производные гуанина и способы их применения
EA200801536A1 (ru) Новые тиенопирсульфоновые производные
RU2019142472A (ru) Глюкуронидные пролекарства ингибиторов янус-киназы
MX2023010125A (es) Inhibidores del sarcomero cardiaco.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
EA202092858A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА
MX2009002905A (es) Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.
MX2022000904A (es) Inhibidores de arginasa y métodos de uso de estos.
MX2023006176A (es) Nuevos derivados de indazol acetileno.
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
MX2023004327A (es) Conjugados terapeuticos radiomarcados y su uso en terapia.